Cel Sci (CVM) Current Leases (2012 - 2026)
Cel Sci (CVM) posted Current Leases of $2.4 million for Q1 2026, up 3.05% sequentially from $2.3 million in Q4 2025, and up 12.94% YoY from $2.1 million in Q1 2025.
Cel Sci (CVM) Current Leases (2012 - 2026) Analysis & Trends
Cel Sci has reported Current Leases for 11 years, with the latest figure at $2.4 million in Q1 2026.
- Quarterly Current Leases rose 12.94% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 12.94% YoY) and the FY2025 annual result came in at $166990.0, down 26.43% from the prior year.
- Current Leases grew to $2.4 million in Q1 2026 per CVM's latest filing, from $2.3 million in the prior quarter.
- Over five years, Current Leases peaked at $2.4 million in Q1 2026 and troughed at $166990.0 in Q3 2025.
- A 5-year average of $817879.3 and a median of $211275.0 in 2024 frame the typical range for Current Leases.
- The widest YoY moves for Current Leases: up 936.84% in 2025, down 90.37% in 2025.
- Over 5 years, Current Leases stood at $170928.0 in 2022, then rose by 19.45% to $204167.0 in 2023, then grew by 10.77% to $226155.0 in 2024, then surged by 936.84% to $2.3 million in 2025, then climbed by 3.05% to $2.4 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $2.4 million, $2.3 million, and $166990.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 2.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.42 Mn |
| Dec 31, 2025 | 2.34 Mn |
| Sep 30, 2025 | 166,990.00 |
| Jun 30, 2025 | 187,739.00 |
| Mar 31, 2025 | 2.14 Mn |
| Dec 31, 2024 | 226,155.00 |
| Sep 30, 2024 | 226,969.00 |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | 211,275.00 |
| Dec 31, 2023 | 204,167.00 |
| Sep 30, 2023 | 197,431.00 |
| Jun 30, 2023 | 190,831.00 |
| Sep 30, 2022 | 170,928.00 |
| Mar 31, 2020 | 977,264.00 |
| Dec 31, 2019 | 964,088.00 |
| Jun 30, 2016 | 2,309.00 |
| Sep 30, 2015 | 9,028.00 |
| Mar 31, 2013 | 7,583.00 |
| Dec 31, 2012 | 7,287.00 |